FDA approves FluMist nasal flu vaccine for at-home use for ages 2-49, starting fall 2025.

The FDA has approved FluMist, a nasal flu vaccine, for at-home use starting in fall 2025. This live vaccine is suitable for individuals aged 2 to 49 and is administered via nasal spray. It is as effective as traditional vaccines but not recommended for those who are immunocompromised or have a history of wheezing. Users should avoid antiviral medications two weeks prior and be cautious if immunodeficient individuals are present in the home.

October 26, 2024
10 Articles

Further Reading